HondurasTuberculosis profile
Population  2014 8 million
Estimates of TB burden * 2014 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.075 (0.075–0.076) 0.95 (0.94–0.95)
Mortality (HIV+TB only) 0.046 (0.034–0.06) 0.58 (0.43–0.75)
Prevalence  (includes HIV+TB) 3.9 (1.5–7.4) 49 (19–92)
Incidence  (includes HIV+TB) 3.4 (3–3.9) 43 (38–48)
Incidence (HIV+TB only) 0.34 (0.3–0.39) 4.3 (3.8–4.9)
         
Case detection, all forms (%) 82 (73–93)    
Estimates of MDR-TB burden * 2014   New   Retreatment
% of TB cases with MDR-TB 1.8 (0.76–3.4) 12 (5.8–22)
MDR-TB cases among notified pulmonary
TB cases
38 (17–75) 25 (12–45)
TB case notifications 2014 New ** Relapse
Pulmonary, bacteriologically confirmed 1 810   180
Pulmonary, clinically diagnosed 380   22
Extrapulmonary 406   22
       
Total new and relapse 2 820    
Previously treated, excluding relapses 0    
Total cases notified 2 820    
Among 2 820 new and relapse cases:
127 (5%) cases aged under 15 years; male:female ratio: 1.6
Reported cases of RR-/MDR-TB 2014 New Retreatment Total **
Cases tested for RR-/MDR-TB 117 (6%) 97 (43%) 219
Laboratory-confirmed RR-/MDR-TB cases     12
Patients started on MDR-TB treatment ***     12
TB/HIV 2014 Number (%)
TB patients with known HIV status 2 479 (88)
HIV-positive TB patients 256 (10)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 203 (79)
HIV-positive TB patients on antiretroviral therapy (ART) 210 (82)
HIV-positive people screened for TB 3 541  
HIV-positive people provided with IPT 249  
Treatment success rate and cohort size (%) Cohort
New cases registered in 2013 (89) 1 924
Previously treated cases registered in 2013 (81) 185
HIV-positive TB cases, all types, registered in 2013 (72) 263
RR-/MDR-TB cases started on second-line treatment in 2012 (40) 5
XDR-TB cases started on second-line treatment in 2012   0
Laboratories 2014  
Smear (per 100 000 population) 2.3
Culture (per 5 million population) 3.8
Drug susceptibility testing (per 5 million population) 0.6
Sites performing Xpert MTB/RIF 0
Is second-line drug susceptibility testing available? Yes, outside
country
Financing TB control 2015  
National TB programme budget (US$ millions) 13
% Funded domestically 17%
% Funded internationally 12%
% Unfunded 71%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
*** Includes patients diagnosed before 2014 and patients who were not laboratory-confirmed as having
RR-/MDR-TB
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2016-05-27 Data: www.who.int/tb/data